Clinical stage II non-small cell lung cancer: can we “just give adjuvant therapy”?
Rajika Jindani, Isaac Loh, Jorge Humberto Rodriguez-Quintero, Grace Ha, Justin Rosario, Brian Cohen, Tamar B Nobel, Marc Vimolratana, Neel P Chudgar, Brendon M Stiles · 2025
Read Clinical stage II non-small cell lung cancer: can we “just give adjuvant therapy”? by Rajika Jindani, Isaac Loh, Jorge Humberto Rodriguez-Quintero, Grace Ha, Justin Rosario, Brian Cohen, Tamar B Nobel, Marc Vimolratana, Neel P Chudgar, Brendon M Stiles (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12780408.txt.
Description
Rajika Jindani and co-authors report a study from two thousand twenty-five on treatment order for stage two lung cancer. Extra therapy after surgery, called adjuvant therapy, helps many patients, but whether all should simply get surgery first was in question. The team used a national cancer database to study patients who had upfront surgery.
They reviewed more than seventeen thousand patients treated between two thousand fifteen and two thousand nineteen. About half of those who had upfront surgery received adjuvant therapy, and staging after surgery raised the stage in nearly a quarter. Older age, more illness, and public insurance linked to lower uptake. In matched groups, patients who got adjuvant therapy lived longer at five years. The authors question whether just giving it later is enough.
Catalog record
| CREATOR | Rajika Jindani, Isaac Loh, Jorge Humberto Rodriguez-Quintero, Grace Ha, Justin Rosario, Brian Cohen, Tamar B Nobel, Marc Vimolratana, Neel P Chudgar, Brendon M Stiles |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 31 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |